Logo

Call us today 212-583-0100

ir@enzo.com    

  • Home
  • Corporate
    • Investor Information
    • About Us
    • Officers & Directors
    • Press Releases
    • Careers
  • Therapeutics
    • About ENZO Therapeutics
      • Overview
      • Our Mission
      • Our Strategy
      • Partnering
      • Maps and Directions
      • Contact Us
    • Therapeutic Market
      • Overview
      • Inflammatory Bowel Disease
      • Uveitis
      • HIV
      • Bone Disorders
      • Diabetes
    • Technologies
      • Immune Regulation
      • Gene Technology
      • Cell Signaling Modulation
    • Pipeline
      • Overview
      • Cell Signaling Modulation
        • Diabetes
        • Preclinical Studies for Bone Disorders
      • Immune Regulation
        • Alequel ™
        • Optiquel ™
      • Gene Technology
        • Stealth Vector™ HGTV43™
  • Clinical Labs
  • Life Sciences
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Jun 03, 2020 4:05pm EDT

Enzo Biochem to Announce Third Quarter 2020 Financial Results on Monday June 8, 2020

May 20, 2020 8:00am EDT

Enzo Biochem Launches Proprietary Test for Detection of Coronavirus SARS-CoV-2 IgG Antibody Under FDA’s Emergency Use Authorization

May 12, 2020 8:00am EDT

Enzo Announces Issuance of U.S. Patent for Methods of Producing Monoclonal Antibodies Against Osteoporosis Drug Target Sclerostin

Apr 29, 2020 8:00am EDT

Enzo Announces Issuance of U.S. Patent for Methods of Using Proprietary Compound SK1-I in Patients; Exploring Options for Development as a Potential Treatment for COVID-19

Apr 23, 2020 8:00am EDT

Enzo Biochem Launches Proprietary COVID-19 Diagnostic Test Under FDA’s Emergency Use Authorization

Mar 24, 2020 7:30am EDT

Enzo Biochem’s Clinical Labs Subsidiary Launches Drive-Through Facility to Provide COVID-19 Testing on Long Island

Mar 06, 2020 8:00am EST

Enzo Biochem’s Full Service Clinical Laboratory to Launch Coronavirus (COVID-19) Testing Services Next Week

Mar 05, 2020 4:05pm EST

Enzo Biochem Reports Fiscal Second Quarter Results

Mar 03, 2020 10:00am EST

Enzo Biochem Schedules Teleconference to Discuss Second Quarter 2020 Results Friday, March 6, 2020 at 8:30 AM E.T.

Feb 25, 2020 9:59am EST

Enzo Biochem Announces Preliminary Results of Voting at Annual Shareholder Meeting

  • Previous
  • 1…
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • …33
  • Next
RSS
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed

Meta

  • Privacy Policy
  • Intellectual Property
  • Safe Harbor Statement
  • HIPAA Policy
  • Web Feedback

Contact us

Enzo Biochem Executive Offices
81 Executive Blvd, Suite 3
Farmingdale, NY
11735
USA

212-583-0100

info@enzo.com

Copyright ©2023 Enzo Biochem Inc.